Novavax has worked tirelessly to develop a successful COVID-19 vaccine candidate. But after manufacturing delays led the company to miss deadlines, it's still trying to prove that its Nuvaxovid's 90% efficacy rate and 100% protection against moderate and severe disease levels is worthy of FDA approval. The company also touts the vaccine's convenience for doctors; it doesn't have to be frozen, making it easier to store and transport.